9 completed, 1 terminated, 1 withdrawn. 5 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
Follow rolapitant: new trials by email Literature Review of rolapitant trials Research Report on rolapitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy Rolapitant, Palonosetron, Olanzapine - Germ Cell Tumor | Phase 2 | Withdrawn | Costantine Albany | 2018-05-01 | 2019-05-22 | |
| Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide Rolapitant, Ondansetron - Chemo-radiation Induced Nausea and Vomiting | Phase 2 | Completed | Duke University | 48 | 2017-10-09 | 2023-07-11 |
| Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy Dexamethasone, Doxorubicin, Fosaprepitant Dimeglumine - Locally Advanced Sarcoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2016-10-12 | 2021-08-09 |
| An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects Rolapitant, Digoxin, Sulfasalazine - Chemotherapy-induced Nausea and Vomiting | Phase 1 | Completed | Tesaro, Inc. | 102 | 2015-05-01 | 2015-08-25 |
| A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers Rolapitant - Chemotherapy-induced Nausea and Vomiting | Phase 1 | Completed | Tesaro, Inc. | 100 | 2015-01-01 | 2015-08-25 |
| An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant Rolapitant - Oral, Rolapitant - IV - Chemotherapy-induced Nausea and Vomiting | Phase 1 | Completed | Tesaro, Inc. | 138 | 2014-09-01 | 2015-08-25 |
| Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy Rolapitant, Granisetron, dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Tesaro, Inc. | 532 | 2012-02-01 | 2016-05-19 |
| Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy Rolapitant, Granisetron, Dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Tesaro, Inc. | 555 | 2012-02-01 | 2016-03-02 |
| Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy Rolapitant, Granisetron, Dexamethasone - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Completed | Tesaro, Inc. | 1369 | 2012-02-01 | 2016-03-02 |
| Study of the Efficacy and Safety of SCH 619734 in Subjects With Chronic Cough From an Unknown Cause (Study P04888) SCH 619734, Placebo Dose 1 - Cough | Phase 2 | Completed | Merck Sharp & Dohme LLC | 35 | 2007-01-01 | 2013-11-27 |
| A Multicenter, Randomized, Controlled Trial of SCH 619734 for the Treatment of Chemotherapy-Induced Nausea and Vomiting (Study P04351AM2)(COMPLETED) SCH 619734 Dose 1, SCH 619734 Dose 2, SCH 619734 Dose 3 - Nausea, Vomiting | Phase 2 | Completed | Schering-Plough | 450 | 2006-09-01 | 2009-10-23 |
Vomiting (8) · Nausea (5) · Cough (1) · Glioma (1) · Neoplasms, Germ Cell and Embryonal (1)
Tesaro, Inc. (6) · Costantine Albany (1) · Duke University (1) · M.D. Anderson Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Schering-Plough (1)
United States (8)
Dennis Vargo, MD (6) · Costantine Albany, MD (1) · Mary Lou Affronti, DNP, RN, ANP, MHSc (1) · Saroj Vadhan (1)